Biofortuna Limited, a Liverpool, UK-based molecular diagnostics company, has raised £1.1m in venture capital funding.
Investors in the round include EV Tech and Catapult Venture Managers.
The funds will be used to launch the company’s first diagnostic genotyping products and to allow it to continue development of its future product pipeline. Biofortuna designs and develops innovative genotyping and antibody screening tests for use in organ transplantation and management, blood banking, disease identification, microbiology and pharmacogenomics.
The company was formed in 2008, securing a research and development grant from the Northwest Development Agency and funding from the Liverpool Seed Fund shortly thereafter. In 2009, Biofortuna signed sales and distribution agreements for European and North African markets, and received regulatory approvals on its first product range.
The management team is led by CEO Mike Bunce and Directors, David Charvill and Ben Passey. Following this funding round, they will be joined by David Whitcombe, who was part of the founding team of DXS, a North West-based molecular diagnostics company sold to Qiagen in 2009.